ArticleOrganic process research & development2026
Insights into Flow and Continuous Systems in Pharmaceutical Manufacturing: Challenges and Opportunities.
Article in Organic process research & development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth and development of the pharmaceutical sector in Ireland has been remarkable over a 50 year period starting as an API manufacturing hub with strong regulatory confidence gradually expanding to include a range of activities ranging from process R&D, formulation services, and other high-value elements of the pharmaceutical enterprise, while in parallel complementary expertise in bioprocessing and biotechnology has resulted in the sector being globally significant and integrated into global supply chains. The more significant change in API manufacture in recent years has been the introduction of continuous flow technology offering many advantages including safety, efficiency, and flexibility. Nevertheless, in such a highly regulated sector navigating the transformation from traditional large-scale batch manufacture to embedding flow technology is not trivial. The Irish landscape, comprising leading multinational API-producing sites, complemented by Contract Development and Manufacturing Organizations (CDMOs) and indigenous companies providing tailored services, has very successfully embraced embedding continuous flow technology for API and RSM manufacture at scale in partnership with the regulatory agencies. In this context, some aspects underpinning this transition are discussed as an informative commentary on the state-of-the-art for the use of flow in API/RSM manufacture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.